Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
Public ClinicalTrials.gov record NCT00193661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Hypogonadism
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to observe efficacy and safety after T-Gel 1% treatment in delayed puberty adolescents. Subjects who complete this trial may enter a 3 month extension study (UMD-01-090E).
Study identification
- NCT ID
- NCT00193661
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 13 Years to 17 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2002 (Type not available)
- Primary completion
- Mar 2007 (Actual)
- Completion
- Mar 2007 (Actual)
- Last update posted
- Jan 16, 2015
2002 – 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 130 | Birmingham | Alabama | — | — |
| Site 107 | Los Angeles | California | — | — |
| Site 113 | Sacramento | California | — | — |
| Site 114 | Torrance | California | — | — |
| Site 121 | Gainesville | Florida | — | — |
| Site 127 | Jacksonville | Florida | — | — |
| Site 128 | Jacksonville | Florida | — | — |
| Site 117 | Indianapolis | Indiana | — | — |
| Site 111 | Kansas City | Missouri | — | — |
| Site 129 | Brooklyn | New York | — | — |
| Site 123 | New York | New York | — | — |
| Site 131 | Cincinnati | Ohio | — | — |
| Site 124 | Columbus | Ohio | — | — |
| Site 103 | Portland | Oregon | — | — |
| Site 109 | Hershey | Pennsylvania | — | — |
| Site 125 | Philadelphia | Pennsylvania | — | — |
| Site 126 | Philadelphia | Pennsylvania | — | — |
| Site 104 | Memphis | Tennessee | — | — |
| Site 205 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00193661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00193661 live on ClinicalTrials.gov.